AGIOS PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$94.63 million for the 3-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-02-24
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$94.63M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$88.77M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$86.22M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was $1.87B.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$117.73M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2014 was -$53.50M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2013 was -$43.57M.
- AGIOS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2012 was -$27.29M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | -$94.63M 10-K · filed 2022-02-24 | -$183.39M derived: sum of 2 quarters · filed 2022-02-24 | -$269.61M derived: sum of 3 quarters · filed 2022-02-24 | $1.60B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2021-09-30 | -$88.77M 10-K · filed 2022-02-24 | -$174.98M derived: sum of 2 quarters · filed 2022-02-24 | $1.70B derived: sum of 3 quarters · filed 2022-02-24 | $1.60B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2021-06-30 | -$86.22M 10-K · filed 2022-02-24 | $1.79B derived: sum of 2 quarters · filed 2022-02-24 | $1.69B derived: sum of 3 quarters · filed 2022-02-24 | $1.59B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2021-03-31 | $1.87B 10-K · filed 2022-02-24 | $1.78B derived: sum of 2 quarters · filed 2022-02-24 | $1.68B derived: sum of 3 quarters · filed 2022-02-24 | $1.59B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-12-31 | -$97.66M 10-K · filed 2022-02-24 | -$196.64M derived: sum of 2 quarters · filed 2022-02-24 | -$287.11M derived: sum of 3 quarters · filed 2022-02-24 | -$327.37M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-09-30 | -$98.98M 10-K · filed 2022-02-24 | -$189.46M derived: sum of 2 quarters · filed 2022-02-24 | -$229.71M derived: sum of 3 quarters · filed 2022-02-24 | -$332.06M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | -$90.48M 10-K · filed 2022-02-24 | -$130.73M derived: sum of 2 quarters · filed 2022-02-24 | -$233.08M derived: sum of 3 quarters · filed 2022-02-24 | -$339.26M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$40.26M 10-K · filed 2022-02-24 | -$142.61M derived: sum of 2 quarters · filed 2022-02-24 | -$248.78M derived: sum of 3 quarters · filed 2022-02-24 | -$358.65M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$102.35M 10-K · filed 2021-02-25 | -$208.52M derived: sum of 2 quarters · filed 2021-02-25 | -$318.39M derived: sum of 3 quarters · filed 2021-02-25 | -$411.47M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-09-30 | -$106.17M 10-K · filed 2021-02-25 | -$216.04M derived: sum of 2 quarters · filed 2021-02-25 | -$309.12M derived: sum of 3 quarters · filed 2021-02-25 | -$400.92M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | -$109.87M 10-K · filed 2021-02-25 | -$202.95M derived: sum of 2 quarters · filed 2021-02-25 | -$294.74M derived: sum of 3 quarters · filed 2021-02-25 | -$389.41M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | -$93.08M 10-K · filed 2021-02-25 | -$184.87M derived: sum of 2 quarters · filed 2021-02-25 | -$279.54M derived: sum of 3 quarters · filed 2021-02-25 | -$348.28M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$91.79M 10-K · filed 2020-02-19 | -$186.46M derived: sum of 2 quarters · filed 2020-02-19 | -$255.20M derived: sum of 3 quarters · filed 2020-02-19 | -$346.03M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-09-30 | -$94.66M 10-K · filed 2020-02-19 | -$163.41M derived: sum of 2 quarters · filed 2020-02-19 | -$254.23M derived: sum of 3 quarters · filed 2020-02-19 | -$342.52M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-06-30 | -$68.75M 10-K · filed 2020-02-19 | -$159.57M derived: sum of 2 quarters · filed 2020-02-19 | -$247.85M derived: sum of 3 quarters · filed 2020-02-19 | -$324.99M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-03-31 | -$90.83M 10-K · filed 2020-02-19 | -$179.11M derived: sum of 2 quarters · filed 2020-02-19 | -$256.25M derived: sum of 3 quarters · filed 2020-02-19 | -$339.33M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2017-12-31 | -$88.28M 10-K · filed 2019-02-14 | -$165.42M derived: sum of 2 quarters · filed 2019-02-14 | -$248.50M derived: sum of 3 quarters · filed 2019-02-14 | -$314.67M derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-09-30 | -$77.14M 10-K · filed 2019-02-14 | -$160.22M derived: sum of 2 quarters · filed 2019-02-14 | -$226.38M derived: sum of 3 quarters · filed 2019-02-14 | -$282.87M derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-06-30 | -$83.08M 10-K · filed 2019-02-14 | -$149.25M derived: sum of 2 quarters · filed 2019-02-14 | -$205.73M derived: sum of 3 quarters · filed 2019-02-14 | -$268.57M derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-03-31 | -$66.17M 10-K · filed 2019-02-14 | -$122.65M derived: sum of 2 quarters · filed 2019-02-14 | -$185.49M derived: sum of 3 quarters · filed 2019-02-14 | -$241.44M derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2016-12-31 | -$56.49M 10-K · filed 2018-02-14 | -$119.32M derived: sum of 2 quarters · filed 2018-02-14 | -$175.27M derived: sum of 3 quarters · filed 2018-02-14 | -$198.47M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-09-30 | -$62.83M 10-K · filed 2018-02-14 | -$118.79M derived: sum of 2 quarters · filed 2018-02-14 | -$141.99M derived: sum of 3 quarters · filed 2018-02-14 | -$182.61M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-06-30 | -$55.95M 10-K · filed 2018-02-14 | -$79.15M derived: sum of 2 quarters · filed 2018-02-14 | -$119.77M derived: sum of 3 quarters · filed 2018-02-14 | -$160.03M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-03-31 | -$23.20M 10-K · filed 2018-02-14 | -$63.82M derived: sum of 2 quarters · filed 2018-02-14 | -$104.08M derived: sum of 3 quarters · filed 2018-02-14 | -$135.97M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2015-12-31 | -$40.62M 10-K · filed 2017-02-16 | -$80.88M derived: sum of 2 quarters · filed 2017-02-16 | -$112.78M derived: sum of 3 quarters · filed 2017-02-16 | -$117.73M 10-K · filed 2016-02-26 | ||
| 2015-09-30 | -$40.26M 10-K · filed 2017-02-16 | -$72.15M derived: sum of 2 quarters · filed 2017-02-16 | -$77.11M 10-Q · filed 2015-11-06 | -$103.78M derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2015-06-30 | -$31.90M 10-K · filed 2017-02-16 | -$36.85M derived: sum of 2 quarters · filed 2017-02-16 | -$63.52M derived: sum of 3 quarters · filed 2017-02-16 | -$59.81M derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2015-03-31 | -$4.96M 10-K · filed 2017-02-16 | -$31.62M derived: sum of 2 quarters · filed 2017-02-16 | -$27.92M derived: sum of 3 quarters · filed 2017-02-16 | -$46.21M derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2014-12-31 | -$26.66M 10-K · filed 2016-02-26 | -$22.96M derived: sum of 2 quarters · filed 2016-02-26 | -$41.26M derived: sum of 3 quarters · filed 2016-02-26 | -$53.50M 10-K · filed 2016-02-26 | ||
| 2014-09-30 | $3.70M 10-K · filed 2016-02-26 | -$14.59M derived: sum of 2 quarters · filed 2016-02-26 | -$26.84M 10-Q · filed 2015-11-06 | -$39.22M derived: sum of 4 quarters · filed 2016-02-26 | ||
| 2014-06-30 | -$18.30M 10-K · filed 2016-02-26 | -$30.54M 10-Q · filed 2014-08-07 | -$42.93M derived: sum of 3 quarters · filed 2016-02-26 | -$54.67M derived: sum of 4 quarters · filed 2016-02-26 | ||
| 2014-03-31 | -$12.25M 10-K · filed 2016-02-26 | -$24.63M derived: sum of 2 quarters · filed 2016-02-26 | -$36.37M derived: sum of 3 quarters · filed 2016-02-26 | -$46.79M derived: sum of 4 quarters · filed 2016-02-26 | ||
| 2013-12-31 | -$12.38M 10-K · filed 2015-02-24 | -$24.13M derived: sum of 2 quarters · filed 2015-02-24 | -$34.54M derived: sum of 3 quarters · filed 2015-02-24 | -$43.57M 10-K · filed 2016-02-26 | ||
| 2013-09-30 | -$11.74M 10-K · filed 2015-02-24 | -$10.61M 10-Q · filed 2013-11-07 | -$22.16M derived: sum of 2 quarters · filed 2015-02-24 | -$31.19M 10-Q · filed 2014-11-07 | -$22.86M 10-Q · filed 2013-11-07 | -$38.30M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$10.42M 10-K · filed 2015-02-24 | -$19.44M 10-Q · filed 2014-08-07 | -$26.55M derived: sum of 3 quarters · filed 2015-02-24 | -$32.99M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-03-31 | -$9.03M 10-K · filed 2015-02-24 | -$16.13M derived: sum of 2 quarters · filed 2015-02-24 | -$22.58M derived: sum of 3 quarters · filed 2015-02-24 | -$29.89M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2012-12-31 | -$7.11M 10-K · filed 2014-03-18 | -$13.55M derived: sum of 2 quarters · filed 2014-03-18 | -$20.86M derived: sum of 3 quarters · filed 2014-03-18 | -$27.29M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | -$6.44M 10-K · filed 2014-03-18 | -$2.85M 10-Q · filed 2013-11-07 | -$13.75M derived: sum of 2 quarters · filed 2014-03-18 | -$9.40M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$7.31M 10-K · filed 2014-03-18 | -$13.74M 10-Q · filed 2013-09-05 | ||||
| 2012-03-31 | -$6.43M 10-K · filed 2014-03-18 | |||||
| 2011-12-31 | -$26.81M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |